Back to Search
Start Over
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
- Source :
-
Clinical lung cancer [Clin Lung Cancer] 2021 Nov; Vol. 22 (6), pp. e851-e855. Date of Electronic Publication: 2021 Apr 27. - Publication Year :
- 2021
- Subjects :
- Female
Humans
Middle Aged
Protein Kinase Inhibitors therapeutic use
Receptor Protein-Tyrosine Kinases
Treatment Outcome
Anaplastic Lymphoma Kinase genetics
Antineoplastic Agents pharmacology
Carbazoles pharmacology
Carcinoma, Non-Small-Cell Lung drug therapy
Crizotinib pharmacology
Drug Resistance, Neoplasm drug effects
Mutation genetics
Piperidines pharmacology
Protein Kinase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0690
- Volume :
- 22
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Clinical lung cancer
- Publication Type :
- Academic Journal
- Accession number :
- 34059475
- Full Text :
- https://doi.org/10.1016/j.cllc.2021.04.008